

ORASURE TECHNOLOGIES INC

Form 8-K

September 09, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 9, 2003

OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

DELAWARE
(State or Other Jurisdiction)

of Incorporation or Organization)

001-16537
(Commission file number)

36-4370966
(I.R.S. Employer

Identification Number)

220 East First Street

Bethlehem, Pennsylvania 18015-1360

(Address of principal executive offices)

(610) 882-1820

(Registrant's telephone number, including area code)

Item 5 Other Events and Regulation FD Disclosure.

OraSure Technologies, Inc. (the Company) issued a press release announcing the receipt of U.S. Food and Drug Administration approval of the Company's OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples. The information contained in the press release dated September 9, 2003 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

Item 7. Financial Statements and Exhibits

(c) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99	Press Release dated September 9, 2003, announcing receipt by OraSure Technologies, Inc. of U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.

Index to Exhibits

Exhibit Number

Description

99

Press Release dated September 9, 2003, announcing receipt by OraSure Technologies, Inc. of receipt of U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.